strong>• Eisai Co. Ltd., of London, received European approval for Halaven (eribulin), a nontaxane, microtubule dynamics inhibitor, in patients with locally advanced or metastatic breast cancer who have progressed after at least two chemotherapeutic regimens for advanced disease.